These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8771087)

  • 21. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
    Catalán MJ; Escribano PM; Alonso-Frech F
    Mov Disord; 2017 Apr; 32(4):624-625. PubMed ID: 28116835
    [No Abstract]   [Full Text] [Related]  

  • 23. Mydriasis in a Parkinson disease patient on low-dose carbidopa/levodopa.
    Burdick DJ; Griffith A; Agarwal P
    Mov Disord; 2013 Mar; 28(3):295. PubMed ID: 23526432
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical significance of cramps of the lower extremities in patients with parkinsonism].
    Yu HZ
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):217-8. PubMed ID: 4075911
    [No Abstract]   [Full Text] [Related]  

  • 25. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion.
    Klostermann F; Jugel C; Bömelburg M; Marzinzik F; Ebersbach G; Müller T
    Mov Disord; 2012 Nov; 27(13):1704-5. PubMed ID: 23192929
    [No Abstract]   [Full Text] [Related]  

  • 26. [Chronic inflammatory demyelinating polyradiculoneuropathy associated with treatment using intraduodenal infusion of levodopa-carbidopa].
    Rivero-de-Aguilar A; Sesar A; Fernandez-Pajarin G; Ares-Pensado B; Castro A
    Rev Neurol; 2019 Oct; 69(7):304-306. PubMed ID: 31559631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cholestasis caused by Nakom].
    Bukhanov VP
    Klin Med (Mosk); 1988 May; 66(5):126-8. PubMed ID: 3419093
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of pregnancy in Parkinson's disease.
    Shulman LM; Minagar A; Weiner WJ
    Mov Disord; 2000 Jan; 15(1):132-5. PubMed ID: 10634252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhaled levodopa (Inbrija) for Parkinson's disease.
    Med Lett Drugs Ther; 2019 May; 61(1572):73-74. PubMed ID: 31169799
    [No Abstract]   [Full Text] [Related]  

  • 31. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Lang AE; Rodriguez RL; Boyd JT; Chouinard S; Zadikoff C; Espay AJ; Slevin JT; Fernandez HH; Lew MF; Stein DA; Odin P; Fung VS; Klostermann F; Fasano A; Draganov PV; Schmulewitz N; Robieson WZ; Eaton S; Chatamra K; Benesh JA; Dubow J
    Mov Disord; 2016 Apr; 31(4):538-46. PubMed ID: 26695437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 33. Parkinson Disease: Current and Emerging Treatment Strategies.
    Ramirez-Zamora A
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29999254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
    Novelli A; Di Vico IA; Terenzi F; Sorbi S; Ramat S
    Parkinsonism Relat Disord; 2019 Jul; 64():352-353. PubMed ID: 31101554
    [No Abstract]   [Full Text] [Related]  

  • 35. Parkinson's disease: recent advances in therapy.
    Jankovic J
    South Med J; 1988 Aug; 81(8):1021-7. PubMed ID: 3043683
    [No Abstract]   [Full Text] [Related]  

  • 36. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skin rash associated with Sinemet does not equal levodopa allergy.
    Chou KL; Stacy MA
    Neurology; 2007 Mar; 68(13):1078-9. PubMed ID: 17389317
    [No Abstract]   [Full Text] [Related]  

  • 38. Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.
    Lehnerer SM; Fietzek UM; Messner M; Ceballos-Baumann AO
    J Neural Transm (Vienna); 2014 Oct; 121(10):1269-72. PubMed ID: 24710647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage.
    Munro Neville A; Parsons RW; Askmark H; Nyholm D
    Parkinsonism Relat Disord; 2012 Jun; 18(5):686-7. PubMed ID: 22197121
    [No Abstract]   [Full Text] [Related]  

  • 40. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.